{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:17:10Z","timestamp":1789078630214,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T00:00:00Z","timestamp":1439337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00259-015-3156-9","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T23:43:28Z","timestamp":1439250208000},"page":"142-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B"],"prefix":"10.1007","volume":"43","author":[{"given":"Katarzyna","family":"Adamczuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Nelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Neyens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vandenbulcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Hilven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,12]]},"reference":[{"key":"3156_CR1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"3156_CR2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer\u2019s disease: a new lexicon. Lancet Neurol 2010;9:1118\u201327.","journal-title":"Lancet Neurol"},{"key":"3156_CR3","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","volume":"78","author":"DS Knopman","year":"2012","unstructured":"Knopman DS, Jack JC, Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576\u201382.","journal-title":"Neurology"},{"key":"3156_CR4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","volume":"12","author":"SJ Vos","year":"2013","unstructured":"Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957\u201365.","journal-title":"Lancet Neurol"},{"key":"3156_CR5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2967\/jnumed.108.060756","volume":"50","author":"M Koole","year":"2009","unstructured":"Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50:818\u201322.","journal-title":"J Nucl Med"},{"key":"3156_CR6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251\u20139.","journal-title":"J Nucl Med"},{"key":"3156_CR7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129\u201335.","journal-title":"Lancet Neurol"},{"key":"3156_CR8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F18). J Nucl Med 2010;51:913\u201320.","journal-title":"J Nucl Med"},{"key":"3156_CR9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"3156_CR10","doi-asserted-by":"crossref","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319\u201329.","DOI":"10.1002\/ana.22068"},{"key":"3156_CR11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 2014;41:290\u2013300.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3156_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ana.22144","volume":"68","author":"WJ Jagust","year":"2010","unstructured":"Jagust WJ. Amyloid imaging: coming to a PET scanner near you. Ann Neurol 2010;68:277\u20138.","journal-title":"Ann Neurol"},{"key":"3156_CR13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.111.094029","volume":"53","author":"Z Csel\u00e9nyi","year":"2012","unstructured":"Csel\u00e9nyi Z, J\u00f6nhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-\u03b2-specific PET radioligand. J Nucl Med 2012;53:415\u201324.","journal-title":"J Nucl Med"},{"key":"3156_CR14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nicl.2013.03.014","volume":"2","author":"R Vandenberghe","year":"2013","unstructured":"Vandenberghe R, Adamczuk K, Dupont P, Van Laere K, Ch\u00e9telat G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer\u2019s disease. Neuroimage Clin 2013;2:497\u2013511.","journal-title":"Neuroimage Clin"},{"key":"3156_CR15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.112.114785","volume":"54","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia. J Nucl Med 2013;54:880\u20136.","journal-title":"J Nucl Med"},{"key":"3156_CR16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.nicl.2013.04.001","volume":"2","author":"K Adamczuk","year":"2013","unstructured":"Adamczuk K, De Weer AS, Nelissen N, Chen K, Sleegers K, Bettens K, et al. Polymorphism of brain derived neurotrophic factor influences \u03b2 amyloid load in cognitively intact apolipoprotein E \u03b54 carriers. Neuroimage Clin 2013;2:512\u201320.","journal-title":"Neuroimage Clin"},{"key":"3156_CR17","doi-asserted-by":"crossref","unstructured":"Adamczuk K, De Weer AS, Nelissen N, Dupont P, Sunaert S, Bettens K, et al. Functional changes in the language network in response to increased amyloid deposition in cognitively intact older adults. Cereb Cortex. 2014. doi: 10.1093\/cercor\/bhu286 .","DOI":"10.1093\/cercor\/bhu286"},{"key":"3156_CR18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/brain\/awm133","volume":"130","author":"N Nelissen","year":"2007","unstructured":"Nelissen N, Vandenbulcke M, Fannes K, Verbruggen A, Peeters R, Dupont P, et al. Abeta amyloid deposition in the language system and how the brain responds. Brain 2007;130:2055\u201369.","journal-title":"Brain"},{"key":"3156_CR19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.euroneuro.2013.10.002","volume":"24","author":"R Ahmad","year":"2014","unstructured":"Ahmad R, Goffin K, Van den Stock J, De Winter FL, Cleeren E, Bormans G, et al. In vivo type 1 cannabinoid receptor availability in Alzheimer\u2019s disease. Eur Neuropsychopharmacol 2014;24:242\u201350.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3156_CR20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 2014;55:1623\u20138.","journal-title":"J Nucl Med"},{"key":"3156_CR21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/jcbfm.1992.81","volume":"12","author":"HW M\u00fcller-G\u00e4rtner","year":"1992","unstructured":"M\u00fcller-G\u00e4rtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571\u201383.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3156_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307\u201310.","journal-title":"Lancet"},{"key":"3156_CR23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"3156_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1\u201315.","journal-title":"Alzheimers Dement"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3156-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-015-3156-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3156-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:06:27Z","timestamp":1558713987000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-015-3156-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1007\/s00259-015-3156-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,12]]}}}